Amedisys Inc AMED
We take great care to ensure that the data presented and summarized in this overview for AMEDISYS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AMED
View all-
Vanguard Group Inc Valley Forge, PA3.21MShares$288 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.1MShares$279 Million0.01% of portfolio
-
Fil LTD Hamilton, D01.31MShares$118 Million0.12% of portfolio
-
Westchester Capital Management, LLC Valhalla, NY1.12MShares$101 Million5.22% of portfolio
-
Pentwater Capital Management LP Naples, FL1.08MShares$96.8 Million1.08% of portfolio
-
State Street Corp Boston, MA951KShares$85.6 Million0.0% of portfolio
-
Alpine Associates Management Inc. Englewood Cliffs, NJ861KShares$77.5 Million3.83% of portfolio
-
Mackenzie Financial Corp Toronto Ontario, A6695KShares$62.5 Million0.1% of portfolio
-
Alliancebernstein L.P. New York, NY664KShares$59.8 Million0.02% of portfolio
-
Magnetar Financial LLC Evanston, IL636KShares$57.2 Million1.78% of portfolio
Latest Institutional Activity in AMED
Top Purchases
Top Sells
About AMED
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.
Insider Transactions at AMED
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 05
2024
|
Nick Muscato Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,421
+25.26%
|
-
|
Jul 31
2024
|
Allyson Guidroz Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,179
+19.67%
|
-
|
Jul 25
2024
|
Allyson Guidroz Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
102
-1.5%
|
$9,894
$97.75 P/Share
|
Jul 25
2024
|
Nick Muscato Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
108
-0.53%
|
$10,476
$97.75 P/Share
|
Jun 26
2024
|
Scott G Ginn EVP, CFO & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,391
-2.87%
|
$219,972
$92.0 P/Share
|
Jun 01
2024
|
Allyson Guidroz Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
175
-2.5%
|
$15,925
$91.15 P/Share
|
May 03
2024
|
Teresa L. Kline Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,678
+17.11%
|
-
|
May 03
2024
|
Vickie L Capps Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,678
+17.11%
|
-
|
May 03
2024
|
Molly Joel Coye Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,678
+19.06%
|
-
|
May 03
2024
|
Allyson Guidroz Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
283
-3.89%
|
$26,036
$92.08 P/Share
|
May 03
2024
|
Ivanetta Davis Samuels Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,678
+22.11%
|
-
|
May 03
2024
|
Jeffrey A Rideout Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,678
+18.0%
|
-
|
May 03
2024
|
Julie D Klapstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,678
+10.48%
|
-
|
May 03
2024
|
Paul B. K. Kusserow Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,678
+0.47%
|
-
|
May 03
2024
|
Bruce D Perkins Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,678
+6.97%
|
-
|
Feb 20
2024
|
Michael Paul North Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,591
-6.65%
|
$147,963
$93.69 P/Share
|
Feb 20
2024
|
Scott G Ginn EVP, CFO & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,218
-3.72%
|
$299,274
$93.69 P/Share
|
Feb 20
2024
|
Nick Muscato Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
327
-1.57%
|
$30,411
$93.69 P/Share
|
Feb 20
2024
|
Denise M. Bohnert Chief Compliance Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,415
-8.2%
|
$131,595
$93.69 P/Share
|
Feb 16
2024
|
Allyson Guidroz Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,143
+22.75%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 125K shares |
---|---|
Exercise of conversion of derivative security | 11.2K shares |
Payment of exercise price or tax liability | 38.4K shares |
---|